1979
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse.
Fisher R, DeVita V, Hubbard S, Simon R, Young R. Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Annals Of Internal Medicine 1979, 90: 761-3. PMID: 434676, DOI: 10.7326/0003-4819-90-5-761.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseProlonged disease-free survivalDisease-free survivalLong-term survivalMOPP chemotherapyMOPP therapyComplete remissionMedian survivalMedian durationRe-treatmentMOPPRemissionHodgkinPatientsRelapseReinductionNitrogen mustardMonthsSurvivalDiseasePrednisoneDurationProcarbazineChemotherapyVincristine
1978
The chemotherapy of Hodgkin's disease. Past experiences and future directions
Devita V, Lewis B, Rozencweig M, Muggia F. The chemotherapy of Hodgkin's disease. Past experiences and future directions. Cancer 1978, 42: 979-990. PMID: 356960, DOI: 10.1002/1097-0142(197808)42:2+<979::aid-cncr2820420721>3.0.co;2-s.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombination chemotherapyAntitumor response rateAdvanced Hodgkin's diseaseComplete remissionDrug therapyDrug combinationsEffective treatmentTherapeutic experimentsAntitumor effectsResponse rateChemotherapyClinical investigatorsNatural historyEffective agentDiseasePatientsMarked increaseTreatmentNitrogen mustardRemissionTherapy
1975
ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY
Devita V, Canellos G, Chabner B, Schein P, Hubbard S, Young R. ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA, A POTENTIALLY CURABLE DISEASE RESULTS WITH COMBINATION CHEMOTHERAPY. The Lancet 1975, 305: 248-250. PMID: 46388, DOI: 10.1016/s0140-6736(75)91142-3.Peer-Reviewed Original ResearchConceptsAdvanced diffuse histiocytic lymphomaDiffuse histiocytic lymphomaCombination chemotherapyHistiocytic lymphomaPatients treated with radiotherapyTreated with combination chemotherapySurvival free of diseaseEvidence of tumorFree of diseaseRecurrence of tumorReticulum-cell sarcomaDefinition of cureModern drug treatmentComplete remissionPartial respondersNon-respondersDrug treatmentPatientsSurvival dataLymphomaRemissionChemotherapyNitrogen mustardTumorTreatment
1970
Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease
LOWENBRAUN S, DEVITA V, SERPICK A. Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease. Blood 1970, 36: 704-717. PMID: 5488687, DOI: 10.1182/blood.v36.6.704.704.Peer-Reviewed Original ResearchConceptsCombination chemotherapyPrior radiotherapyHodgkin's diseaseProgressive Hodgkin's diseaseStage IV diseaseRemission 1Previous therapyComplete responseNitrogen mustardPartial responseTherapy completionSystemic symptomsDrug combinationsChemotherapyPatientsDay 1Drug AdministrationRadiotherapyPrednisoneDiseasePoor toleranceVincristineCycle 1TherapyI.V.Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma
Lowenbraun S, DeVita V, Serpick A. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970, 25: 1018-1025. PMID: 4910254, DOI: 10.1002/1097-0142(197005)25:5<1018::aid-cncr2820250505>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsReticulum cell sarcomaComplete remissionPartial remissionRCS patientsCell sarcomaLSA patientsUnmaintained complete remissionOnset of therapyCombination of agentsGeneralized lymphosarcomaModerate myelosuppressionCombination chemotherapyRC patientsTherapy completionMean durationPatientsRemissionLymphosarcomaSarcomaVincristineDiseaseNitrogen mustardSurvivalSubstantial durationDuration